Cumulative incidence of hospitalization or urgent care due to heart failure, all severe hypoglycemic events, and discontinuation of study drug
| . | Age ≥ 65 y . | . | . | Age < 65 y . | . | . | . |
|---|---|---|---|---|---|---|---|
| . | DU (N = 2619) . | PL (N = 2637) . | HR or RR (95% CI) . | DU (N = 2330) . | PL (N = 2315) . | HR or RR (95% CI) . | Interaction P . |
| Hospitalization or urgent care due to heart failure | |||||||
| Patients with events, n (%) | 138 (5.3) | 152 (5.8) | HR: 0.90 (0.72-1.14) | 75 (3.2) | 74 (3.2) | HR: 0.99 (0.72-1.37) | .636 |
| All severe hypoglycemic events | |||||||
| Patients with events, n (%) | 46 (1.8) | 49 (1.9) | HR: 0.94 (0.63-1.41) | 18 (0.8) | 25 (1.1) | HR: 0.71 (0.39-1.30) | .443 |
| All events | 57 | 53 | RR: 1.08 (0.68-1.72) | 20 | 29 | RR: 0.69 (0.36-1.31) | .259 |
| Discontinuation of study drug | |||||||
| Discontinuation due to any reason, n (%) | 985 (37.6) | 1013 (38.4) | HR: 0.99 (0.91-1.09) | 632 (27.1) | 681 (29.4) | HR: 0.91 (0.82-1.01) | .209 |
| Discontinuation due to adverse event, n (%) | 289 (11.0) | 200 (7.6) | HR: 1.50 (1.25-1.79) | 162 (7.0) | 110 (4.8) | HR: 1.47 (1.16-1.88) | .921 |
| . | Age ≥ 65 y . | . | . | Age < 65 y . | . | . | . |
|---|---|---|---|---|---|---|---|
| . | DU (N = 2619) . | PL (N = 2637) . | HR or RR (95% CI) . | DU (N = 2330) . | PL (N = 2315) . | HR or RR (95% CI) . | Interaction P . |
| Hospitalization or urgent care due to heart failure | |||||||
| Patients with events, n (%) | 138 (5.3) | 152 (5.8) | HR: 0.90 (0.72-1.14) | 75 (3.2) | 74 (3.2) | HR: 0.99 (0.72-1.37) | .636 |
| All severe hypoglycemic events | |||||||
| Patients with events, n (%) | 46 (1.8) | 49 (1.9) | HR: 0.94 (0.63-1.41) | 18 (0.8) | 25 (1.1) | HR: 0.71 (0.39-1.30) | .443 |
| All events | 57 | 53 | RR: 1.08 (0.68-1.72) | 20 | 29 | RR: 0.69 (0.36-1.31) | .259 |
| Discontinuation of study drug | |||||||
| Discontinuation due to any reason, n (%) | 985 (37.6) | 1013 (38.4) | HR: 0.99 (0.91-1.09) | 632 (27.1) | 681 (29.4) | HR: 0.91 (0.82-1.01) | .209 |
| Discontinuation due to adverse event, n (%) | 289 (11.0) | 200 (7.6) | HR: 1.50 (1.25-1.79) | 162 (7.0) | 110 (4.8) | HR: 1.47 (1.16-1.88) | .921 |
Abbreviations: DU, dulaglutide; HR, hazard ratio; PL, placebo; RR, rate ratio.
Cumulative incidence of hospitalization or urgent care due to heart failure, all severe hypoglycemic events, and discontinuation of study drug
| . | Age ≥ 65 y . | . | . | Age < 65 y . | . | . | . |
|---|---|---|---|---|---|---|---|
| . | DU (N = 2619) . | PL (N = 2637) . | HR or RR (95% CI) . | DU (N = 2330) . | PL (N = 2315) . | HR or RR (95% CI) . | Interaction P . |
| Hospitalization or urgent care due to heart failure | |||||||
| Patients with events, n (%) | 138 (5.3) | 152 (5.8) | HR: 0.90 (0.72-1.14) | 75 (3.2) | 74 (3.2) | HR: 0.99 (0.72-1.37) | .636 |
| All severe hypoglycemic events | |||||||
| Patients with events, n (%) | 46 (1.8) | 49 (1.9) | HR: 0.94 (0.63-1.41) | 18 (0.8) | 25 (1.1) | HR: 0.71 (0.39-1.30) | .443 |
| All events | 57 | 53 | RR: 1.08 (0.68-1.72) | 20 | 29 | RR: 0.69 (0.36-1.31) | .259 |
| Discontinuation of study drug | |||||||
| Discontinuation due to any reason, n (%) | 985 (37.6) | 1013 (38.4) | HR: 0.99 (0.91-1.09) | 632 (27.1) | 681 (29.4) | HR: 0.91 (0.82-1.01) | .209 |
| Discontinuation due to adverse event, n (%) | 289 (11.0) | 200 (7.6) | HR: 1.50 (1.25-1.79) | 162 (7.0) | 110 (4.8) | HR: 1.47 (1.16-1.88) | .921 |
| . | Age ≥ 65 y . | . | . | Age < 65 y . | . | . | . |
|---|---|---|---|---|---|---|---|
| . | DU (N = 2619) . | PL (N = 2637) . | HR or RR (95% CI) . | DU (N = 2330) . | PL (N = 2315) . | HR or RR (95% CI) . | Interaction P . |
| Hospitalization or urgent care due to heart failure | |||||||
| Patients with events, n (%) | 138 (5.3) | 152 (5.8) | HR: 0.90 (0.72-1.14) | 75 (3.2) | 74 (3.2) | HR: 0.99 (0.72-1.37) | .636 |
| All severe hypoglycemic events | |||||||
| Patients with events, n (%) | 46 (1.8) | 49 (1.9) | HR: 0.94 (0.63-1.41) | 18 (0.8) | 25 (1.1) | HR: 0.71 (0.39-1.30) | .443 |
| All events | 57 | 53 | RR: 1.08 (0.68-1.72) | 20 | 29 | RR: 0.69 (0.36-1.31) | .259 |
| Discontinuation of study drug | |||||||
| Discontinuation due to any reason, n (%) | 985 (37.6) | 1013 (38.4) | HR: 0.99 (0.91-1.09) | 632 (27.1) | 681 (29.4) | HR: 0.91 (0.82-1.01) | .209 |
| Discontinuation due to adverse event, n (%) | 289 (11.0) | 200 (7.6) | HR: 1.50 (1.25-1.79) | 162 (7.0) | 110 (4.8) | HR: 1.47 (1.16-1.88) | .921 |
Abbreviations: DU, dulaglutide; HR, hazard ratio; PL, placebo; RR, rate ratio.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
